.
MergerLinks Header Logo

New Deal


Announced

Completed

Flagship Pioneering led a $189m Series B round in Repertoire Immune Medicines.

Financials

Edit Data
Transaction Value£137m
Consideration TypeCash
Capital Owned-
Capital Bid For-
EV/Sales-
EV/EBITDA-
Share Price Premium-
One Off Charge-

Tags

Edit

Completed

Acquisition

Venture Capital

Friendly

Biotechnology

Minority

Single Bidder

Private Equity

clinical-stage biotech

Private

United States

Cross Border

Synopsis

Edit

Flagship Pioneering led a $189m Series B round in Repertoire Immune Medicines, a clinical-stage biotech company, with participation from Softbank Vision Fund 2, PSP Investments, Alaska Permanent Fund and Invus. Proceeds from this financing will support further expansion of the company’s proprietary DECODE discovery platform, accelerate its clinical and preclinical pipeline, expand Repertoire’s team, and enhance its manufacturing capabilities.

© COPYRIGHT 2024 MERGERLINKS LIMITED.

ALL RIGHTS RESERVED.

15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.

CONTACT US